12 results on '"B. Bouchacourt"'
Search Results
2. P1329: POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) VERSUS ANTITHYMOCYTE GLOBULIN (ATG) AS GVHD PROPHYLAXIS FOR MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION.
- Author
-
F. Dachy, S. Furst, B. Calmels, T. Pagliardini, S. Harbi, B. Bouchacourt, A. Calleja, C. Lemarie, A. Collignon, G. Morel, F. Legrand, E. Bekrieva, A. Granata, P. J. Weiller, C. Chabannon, J. M. Schiano de Collela, N. Vey, D. Blaise, and R. Devillier
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
3. O-09: DURABLE ENGRAFTMENT AFTER PHARMACOLOGICAL PRE-TRANSPLANT IMMUNOSUPPRESSION FOLLOWED BY REDUCED-TOXICITY MYELOABLATIVE HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN HIGHLY HLA-IMMUNIZED ADULTS WITH SICKLE CELL DISEASE
- Author
-
S., FÜRST, primary, E., BERNIT, additional, A., GRANATA, additional, F., LEGRAND, additional, S., HARBI, additional, R., DEVILLIER, additional, V., MAISANO, additional, B., BOUCHACOURT, additional, T., PAGLIARDINI, additional, D., MOKART, additional, C., LEMARIÉ, additional, B., CALMELS, additional, C., PICARD, additional, A., BASIRE, additional, C., CHABANNON, additional, B., ANDERSSON, additional, and D., BLAISE, additional
- Published
- 2022
- Full Text
- View/download PDF
4. Néphropathies au cours de la leucémie lymphoïde chronique : à propos d’une étude monocentrique de 10 cas
- Author
-
R. Vial, L Swiader, M. Devos, Marion Sallée, H. Sichez, M. Lankester, Karin Mazodier, B. Bouchacourt, Jean-Robert Harlé, Laurent Daniel, G. Cazajous, J. Seguier, Noémie Jourde-Chiche, and P. Gobert
- Subjects
03 medical and health sciences ,0302 clinical medicine ,030232 urology & nephrology ,Gastroenterology ,Internal Medicine ,030215 immunology - Abstract
Resume Introduction La leucemie lymphoide chronique (LLC) est une hemopathie maligne, associee a une proliferation de lymphocytes B matures. Elle represente une incidence de 4400 nouveaux cas par an en France. La prevalence de la maladie augmente avec l’âge, avec une mediane d’âge au diagnostic autour de 65 ans. Les atteintes renales justifiant une biopsie renale sont evaluees a 1,2 % des patients. L’histologie retrouvee reste tres variable et n’est pas toujours en lien avec la pathologie lymphoide. Nous proposons de repertorier les cas de biopsies renales obtenues chez des patients atteints de LLC au CHU de Marseille. Patients et methodes Les patients atteints d’une LLC et ayant beneficie d’une biopsie renale au CHU de Marseille entre 2000 et mars 2016 ont ete inclus. Les resultats histologiques etaient interpretes par un seul anatomopathologiste. Les donnees etaient collectees le jour de la biopsie et le suivi des patients etait recueilli. Resultats Au total, 10 patients atteints d’une LLC ont beneficie d’une biopsie renale durant la periode de l’etude. Les indications de biopsie renale etaient une insuffisance renale aigue organique ou la presence d’un syndrome nephrotique. Les atteintes retrouvees etaient une glomerulonephrite extramembraneuse (GEM) sans anticorps anti-PLA2R pour 4 patients, 1 syndrome nephrotique a lesions glomerulaires minimes, 1 glomerulonephrite membrano-proliferative associee a une cryoglobulinemie, 1 amylose AL, 1 glomerulonephrite fibrillaire non amyloide, 1 tubulopathie et 1 nephrite interstielle par infiltration lymphoide. Seul 1 patient etait traite avant la biopsie, 7 autres ont ete traites du fait de l’atteinte renale, avec des reponses variables sur le plan hematologique et renal. Conclusion Les atteintes renales associees a la LLC sont rares et de presentation variable. Elles ne sont pas integrees aux criteres classiques de la classification de Binet. Elles peuvent etre responsables d’une insuffisance renale severe ou d’un syndrome nephrotique, et conduisent cependant frequemment a initier un traitement de la LLC. La presentation la plus frequente de cette serie etait la GEM secondaire, ce qui n’etait pas le cas dans la litterature.
- Published
- 2018
- Full Text
- View/download PDF
5. Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome
- Author
-
B. Bouchacourt, M. A. Hospital, C. Zemmour, J. Rey, E. d’Incan, A. Charbonnier, B. Mohty, C. Saillard, S. Bonnet, A. Collignon, V. Gelsi-Boyer, M. J. Mozziconacci, D. Blaise, and N. Vey
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Blood Component Transfusion ,Hematopoietic stem cell transplantation ,Kaplan-Meier Estimate ,Transplantation, Autologous ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Aged ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,Hematology ,business.industry ,Daunorubicin ,Remission Induction ,Cytarabine ,Hematopoietic Stem Cell Transplantation ,Myeloid leukemia ,Retrospective cohort study ,General Medicine ,Middle Aged ,Allografts ,Combined Modality Therapy ,Consolidation Chemotherapy ,Regimen ,Leukemia, Myeloid, Acute ,surgical procedures, operative ,Platelet transfusion ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,business ,030215 immunology ,medicine.drug ,Follow-Up Studies - Abstract
Although complete remission (CR) is achieved in 50 to 70% of older fit patients with acute myeloid leukemia (AML), consolidation therapy in this age group remains challenging. In this retrospective study, we aimed to compare outcome in elderly patients treated with different post-remission modalities, including allogenic and autologous hematopoietic stem cell transplantation (HSCT), intensive chemotherapy, and standard-dose chemotherapy (repeated 1 + 5 regimen). We collected data of 441 patients ≥ 60 years in first CR from a single institution. Median age was 67 years. Sixty-one (14%) patients received allo-HSCT, 51 (12%) auto-HSCT, 70 (16%) intensive chemotherapy with intermediate- or high-dose cytarabine (I/HDAC), and 190 (43%) 1 + 5 regimen. Median follow-up was 6.5 years. In multivariate analysis, allo-HSCT, cytogenetics, and PS had a significant impact on OS and LFS. In spite of a more favorable-risk profile, the patients who received I/HDAC had no significantly better LFS as compared with patients treated with 1 + 5 (median LFS 8.8 months vs 10.6 months, p = 0.96). In transplanted patients, median LFS was 13.3 months for auto-HSCT and 25.8 months for allo-HSCT. Pre-transplant chemotherapy with I/HDAC had no effect on the outcome. Toxicity was significantly increased for both transplanted and non-transplanted patients treated with I/HDAC, with more units of blood and platelet transfusion and more time spent in hospitalization, but no higher non-relapse mortality. This study shows that post-remission chemotherapy intensification is not associated with significantly better outcome as compared with standard-dose chemotherapy in elderly patients for whom, overall results remain disappointing.
- Published
- 2019
6. [Chronic lymphoid leukemia and renal complication: Report on 10 cases from Marseille over 16 years]
- Author
-
R, Vial, L, Daniel, M, Devos, B, Bouchacourt, G, Cazajous, H, Sichez, K, Mazodier, M, Lankester, P, Gobert, J, Seguier, L, Swiader, M, Sallée, N, Jourde-Chiche, and J-R, Harlé
- Subjects
Aged, 80 and over ,Male ,Nephrotic Syndrome ,Paraneoplastic Syndromes ,Nephrosis, Lipoid ,Amyloidosis ,Acute Kidney Injury ,Middle Aged ,Kidney ,Glomerulonephritis, Membranous ,Leukemia, Lymphocytic, Chronic, B-Cell ,Glomerulonephritis ,Leukemic Infiltration ,Humans ,Female ,Kidney Diseases ,France ,Aged ,Retrospective Studies - Abstract
Chronic lymphoid leukemia (CLL) is a hematological malignant disease, associated with a clonal B cell proliferation. The incidence is 4400 new cases per year in France. The prevalence increases with age with a median age at diagnostic of 65 years. Renal involvement is rare and estimated at 1.2% of patients with CLL. Renal pathological diagnoses associated with CLL are variable and are not always related to the hematological disease. We report here on cases of patients with CLL who underwent a renal biopsy over the past 16 years in Marseille.All cases of renal biopsies performed in patients with CLL between2000 and 2016 in Marseille were included. Pathological analysis was performed by the same experimented pathologist. Data were collected at the time of biopsy and after treatment.Ten patients were included in this study. The reason for renal biopsy was acute kidney injury or the onset of nephrotic syndrome. We report on 4 cases of membranous nephropathy, 1 minimal change disease, 1 cryglobulinemia-related membrano-proliferative glomerulonephritis, 1 light chain amyloidosis, 1 fibrillary glomerulonephritis, 1 interstitial monoclonal infiltration and one case of non-specific tubular lesions. Only one patient was treated before the biopsy, 7 patients received a specific hematological treatment of CLL because of its renal involvement. Renal and hematological responses were variable.Renal involvement of CLL is rare and is not mentioned in the Binet classification. Yet, it can be severe, with acute kidney injury or nephrotic syndrome, and can lead to the initiation of a specific treatment. The most frequent presentation this series was secondary MN, which differs from previous series.
- Published
- 2017
7. Vertiges de l’angoisse : un cas d’épilepsie vestibulaire
- Author
-
M. Ete, Pierre-Jean Weiller, B. Bouchacourt, Audrey Benyamine, P. Belenotti, F. Bartholomei, Jean-Robert Harlé, and M. Artuis
- Subjects
0301 basic medicine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Gastroenterology ,Internal Medicine ,030217 neurology & neurosurgery - Abstract
Introduction Les explorations de symptomatologies vertigineuses sont souvent laborieuses des que ceux-ci ne sont ni d’origine peripherique ni d’origine centrale. L’hypothese psychosomatique est parfois proposee notamment chez une personne jeune. Nous rapportons un cas d’epilepsie vestibulaire de diagnostic difficile. Observation Un jeune de 35 ans etait adresse en consultation pour une asthenie inexpliquee et des malaises atypiques evoluant depuis 2013. Ces malaises survenaient notamment lors de discussions soutenues ou de stimulation visuelle. Le stress et les emotions declenchaient egalement ces sensations d’instabilite. Il etait gene dans sa vie quotidienne au point d’avoir arreter les competitions de planche a voile. Il avait comme seul antecedent une thyroidite d’Hashimoto avec des anticorps anti-TPO tres positifs equilibree par opotherapie substitutive. L’examen clinique ne retrouvait pas de syndrome vestibulaire central ou peripherique. Le patient signalait par ailleurs des troubles de l’attention et parfois des troubles de l’elocution mais toujours en contexte anxiogene. L’IRM cerebrale etait normale. L’electroencephalogramme realise mettait en evidence des anomalies irritatives soit sous la forme de bouffees assez degradees de pointes et d’ondes lentes, soit la presence d’activites pointues dans la region temporo-parieto-occipitale a predominance droite. Ces anomalies etaient confirmees sur l’electroencephalogramme de sieste. L’instauration d’un traitement par benzodiazepine a permis la resolution des crises. Discussion Les epilepsies vestibulaires se rencontrent plus chez le sujet jeune et sont generalement d’evolution favorable [1] . Elles peuvent se traduire par des manifestations d’instabilite comme chez notre patient ou de grands vertiges en fonction de la topographie de la zone epileptogene. Elles peuvent reveler des cavernomes temporales et justifient une imagerie cerebrale [2] . Conclusion Les epilepsies vestibulaires peuvent se reveler par des manifestations atypiques minimes mais invalidants. L’association de signes de la lignee epileptique (manifestations neurologiques autres transitoires) permet d’evoquer le diagnostic et d’instaurer une therapeutique specifique.
- Published
- 2016
- Full Text
- View/download PDF
8. Adaptive dosing of high-dose busulfan in real-world adult patients undergoing haematopoietic cell transplant conditioning.
- Author
-
Protzenko D, Bouchacourt B, Carriat L, Maroselli P, Boéri C, Devillier R, and Ciccolini J
- Abstract
Aim: To evaluate the effectiveness of a Bayesian adaptive dosing strategy in achieving target busulfan exposure in adult patients undergoing haematopoietic cell transplantation (HCT)., Methods: This study included 71 adult patients scheduled to receive high-dose busulfan. Busulfan was administered to achieve a cumulative area under the curve (AUC) of 66.0 mg/L/h (16 000 μM/min), 82.60 mg/L/h (20 000 μM/min) or 87.6 mg/L/h (21 200 μM/min) depending on the regimen. Individual pharmacokinetic (PK) parameters of busulfan were estimated from three blood samples using a one-compartment model and Bayesian estimation after the first standard dose. Individual PK parameters were used to adjust subsequent doses to achieve the target exposure., Results: All patients had their dose adjusted after the first dose administration. The final deviation from the target AUC was significantly improved compared to the initial deviation after standard mg/kg dosing (mean absolute deviation 19.5% vs 11.7%, P < .01). In addition, the proportion of patients with marked deviation from target exposure (ie, >25%) decreased significantly from 31% after standard dosing to 10% after PK-guided dosing (P < .01). Canonical busulfan-related toxicity, specifically veno-occlusive disease, was observed in 5% of patients who achieved successful PK-guided dosing. In contrast, one-third of patients with off-target exposure with poor dosing experienced toxicity., Conclusion: The Bayesian adaptive dosing strategy significantly improves the accuracy of achieving the target busulfan AUC in patients undergoing HCT. This approach not only reduces marked deviations from target exposure, but also reduces the incidence of busulfan-related toxicity, thereby maintaining a favourable toxicity/efficacy ratio., (© 2024 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)
- Published
- 2024
- Full Text
- View/download PDF
9. Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell disease.
- Author
-
Fürst S, Bernit E, Legrand F, Granata A, Harbi S, Devillier R, Maisano V, Bouchacourt B, Pagliardini T, Mokart D, Lemarié C, Calmels B, Picard C, Basire A, Andersson BS, and Blaise D
- Subjects
- Humans, Adult, Male, Female, Hematopoietic Stem Cell Transplantation methods, Transplantation, Haploidentical methods, Young Adult, Cyclophosphamide therapeutic use, Cyclophosphamide pharmacology, Graft vs Host Disease prevention & control, Anemia, Sickle Cell therapy, Transplantation Conditioning methods, HLA Antigens immunology
- Abstract
Allogeneic stem cell transplantation (Allo-SCT) is the only rapidly available curative treatment modality in patients with severe sickle cell disease (SCD). The development of reduced-toxicity myeloablative conditioning (RT-MAC) regimen and the use of partially matched family donors with post-transplantation cyclophosphamide (PT-Cy) have widened the access to Allo-SCT. Antibodies against donor-specific HLA (DSA) increase the risk of engraftment failure in HLA mismatched Allo-SCT. We report the results of five patients with SCD, whereas three with DSA, who underwent an unmanipulated haploidentical stem cell transplantation (Haplo-SCT) after a busulfan-based RT-MAC regimen with PT-Cy. To reduce the risk of engraftment failure, a sequential two courses pharmacological pre-transplant immune suppression (PTIS) phase was added prior to the conditioning regimen. All patients engrafted successfully. The procedure was well tolerated. None of the patients developed acute GVHD, whereas one developed moderate chronic GVHD. After a median follow-up of 5 years (range, 2.2-9), all patients are free of pain with excellent quality of life. Our report shows that Haplo-SCT after a RT-MAC regimen is feasible and safe with stable long-term engraftment and excellent disease control. The risk of graft failure can be abrogated by adding a PTIS phase prior to initiating the conditioning regimen., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF
10. Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome.
- Author
-
Harbi S, Brac de la Perriere L, Bouchacourt B, Garciaz S, Pagliardini T, Calmels B, Cecile M, Lefloch AC, Hicheri Y, Hospital MA, Fürst S, Lemarie C, Braticevic C, Legrand F, Bekrieva E, Weiller PJ, Chabannon C, Vey N, Blaise D, and Devillier R
- Subjects
- Aged, Humans, Cyclophosphamide therapeutic use, Recurrence, Retrospective Studies, Transplantation Conditioning, Graft vs Host Disease etiology, Hematopoietic Stem Cell Transplantation adverse effects, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
- Abstract
Haploidentical stem cell transplantation (Haplo-SCT) using non-myeloablative conditioning regimen (NMAC) has extended the feasibility of allogeneic transplantation, notably in older patients. However, there is few data specifically focusing on patients aged 70 years and over with AML and MDS. Thus the benefit of transplantation in this population is still debated. Here we report our single center experience of peripheral blood Haplo-SCT with NMAC and post-transplantation cyclophosphamide in AML and MDS patients aged 70 years and over. We analyzed 50 patients (27 AML, 23 MDS) with a median age of 72 years (70-77), 12/50 (24%) with active disease at Haplo-SCT. Cumulative incidence of grade 3-4 acute and moderate or severe chronic GVHD were 6% and 25%, respectively. Non-relapse mortality (NRM) at day +100 was 0%. NRM, relapse, PFS and OS at 3 years were 16%, 18%, 66%, and 69%, respectively. Among patients who were disease free at 2 years post Haplo-SCT, 88% are living without immunosuppressive treatment. Peripheral blood Haplo-SCT is feasible in selected AML/MDS patients over 70 years, without any early NRM. It produces long-term disease control and survival. Thus, age by itself should not be considered as a formal barrier to Haplo-SCT., (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF
11. GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation.
- Author
-
Dachy F, Furst S, Calmels B, Pagliardini T, Harbi S, Bouchacourt B, Calleja A, Lemarie C, Collignon A, Morel G, Legrand F, Bekrieva E, Granata A, Weiller PJ, Chabannon C, Schiano JM, Vey N, Blaise D, and Devillier R
- Subjects
- Humans, Antilymphocyte Serum therapeutic use, Incidence, Immunosuppressive Agents therapeutic use, Cyclophosphamide therapeutic use, Unrelated Donors, Retrospective Studies, Hematopoietic Stem Cell Transplantation methods, Graft vs Host Disease etiology
- Published
- 2023
- Full Text
- View/download PDF
12. Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
- Author
-
Bouchacourt B, Hospital MA, Zemmour C, Rey J, d'Incan E, Charbonnier A, Mohty B, Saillard C, Bonnet S, Collignon A, Gelsi-Boyer V, Mozziconacci MJ, Blaise D, and Vey N
- Subjects
- Aged, Aged, 80 and over, Allografts, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Blood Component Transfusion, Combined Modality Therapy, Cytarabine administration & dosage, Cytarabine adverse effects, Daunorubicin administration & dosage, Daunorubicin adverse effects, Disease-Free Survival, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute therapy, Male, Middle Aged, Remission Induction, Retrospective Studies, Transplantation, Autologous, Treatment Outcome, Consolidation Chemotherapy, Leukemia, Myeloid, Acute drug therapy
- Abstract
Although complete remission (CR) is achieved in 50 to 70% of older fit patients with acute myeloid leukemia (AML), consolidation therapy in this age group remains challenging. In this retrospective study, we aimed to compare outcome in elderly patients treated with different post-remission modalities, including allogenic and autologous hematopoietic stem cell transplantation (HSCT), intensive chemotherapy, and standard-dose chemotherapy (repeated 1 + 5 regimen). We collected data of 441 patients ≥ 60 years in first CR from a single institution. Median age was 67 years. Sixty-one (14%) patients received allo-HSCT, 51 (12%) auto-HSCT, 70 (16%) intensive chemotherapy with intermediate- or high-dose cytarabine (I/HDAC), and 190 (43%) 1 + 5 regimen. Median follow-up was 6.5 years. In multivariate analysis, allo-HSCT, cytogenetics, and PS had a significant impact on OS and LFS. In spite of a more favorable-risk profile, the patients who received I/HDAC had no significantly better LFS as compared with patients treated with 1 + 5 (median LFS 8.8 months vs 10.6 months, p = 0.96). In transplanted patients, median LFS was 13.3 months for auto-HSCT and 25.8 months for allo-HSCT. Pre-transplant chemotherapy with I/HDAC had no effect on the outcome. Toxicity was significantly increased for both transplanted and non-transplanted patients treated with I/HDAC, with more units of blood and platelet transfusion and more time spent in hospitalization, but no higher non-relapse mortality. This study shows that post-remission chemotherapy intensification is not associated with significantly better outcome as compared with standard-dose chemotherapy in elderly patients for whom, overall results remain disappointing.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.